Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Depression in Patients Being Treated for Head and Neck Cancer.

Next Previous
Trial Profile

Prevention of Depression in Patients Being Treated for Head and Neck Cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Depressive disorders
  • Focus Therapeutic Use
  • Acronyms PROTECT

Most Recent Events

  • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
  • 22 Mar 2013 Primary endpoint 'Quick-Inventory-of-Depressive-Symptomology-Self-Report' has been met according to results presented at the 166th Annual Meeting of the American Psychiatric Association.
  • 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top